Last edition
News about "Ghassan Abou-Alfa"
Imfinzi Combo Improves PFS in Unresectable Liver Cancer in Phase 3 EMERALD-3 Trial
Imfinzi-based combination improves progression-free survival and shows a trend towards overall survival benefit in unresectable liver cancer in the Phase 3 EMERALD-3 trial.
Ghassan Abou-Alfa | 04/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members